- Several pharmacologic inhibitors of matrix metalloproteinases are presently available and many are being tested in clinical trials. An understanding of the role of proteinases in the normal and diseased brain is critical if these drugs are to be used wisely- Includes contributions from leaders in the field of metalloproteinase biology comprising Chris Overall, Dylan Edwards, Wee Yong, John Sandy, David Muir, Iain Campbell, Gary Rosenberg, Jasti Rao, Jeanine D'Armiento, Dieter Zimmerman, and Paul Gottschall